Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 4/20 | 0.41 |
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | CASP3 | P42574 | 4/20 | 0.41 |
| ▸ | CASP2 | P42575 | 4/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083059 | 0.90 | DPP4 (0.47) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL16468657 | 0.86 | ACE (0.50) | CALCRLCASP3CASP2 | |
| SCHEMBL2185084 | 0.84 | CALCRL (0.48) | CALCRLCASP3CASP2 | |
| SCHEMBL30525434 | 0.81 | CALCRL (0.50) | CALCRL | |
| SCHEMBL30525445 | 0.78 | CAPN1 (0.53) | CALCRL | |
| SCHEMBL30401176 | 0.77 | SLC6A2 (0.49) | CALCRL | |
| SCHEMBL30051863 | 0.77 | ACE (0.49) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL7406032 | 0.76 | DPP4 (0.62) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL7029434 | 0.76 | DPP4 (0.62) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL29521253 | 0.76 | CALCRL (0.49) | CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054519-A1 | DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | claimed |
| EP-1915160-A2 | DERIVATIVES OF MONOSACCHARIDES FOR THE TREATMENT OF COPD AND ALLERGIC RHINITIS | Ranbaxy Laboratories Limited (IN) | 2008-04-30 | — | — | EP | claimed |
| WO-2007010499-A2 | DERIVATIVES OF MONOSACCHARIDES FOR THE TREATMENT OF COPD AND ALLERGIC RHINITIS | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-25 | — | — | WO | claimed |
| CN-1254478-C | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2006-05-03 | — | — | CN | claimed |
| WO-2004071515-A1 | PREPARATION OF MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-26 | — | — | WO | claimed |
| EP-1144425-B1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LAB LTD (IN) | 2004-06-16 | — | — | EP | claimed |
| CN-1343212-A | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | claimed |
| US-6329344-B1 | UREA DERIVATIVE OF ALKYLENE DIOXYFURAN ETHERS | RANBAXY LABORATORIES LIMITED (IN) | 2001-12-11 | — | — | US | claimed |
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | claimed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | claimed |
| US-7790689-B2 | Monosaccharide derivatives | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-07 | — | — | US | disclosed |
| US-20090054519-A1 | DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-26 | — | — | US | disclosed |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-19 | — | — | US | disclosed |
| US-20080300196-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1953170-A1 | Monosaccharide derivatives as anti-inflammatory agents | Ranbaxy Laboratories Limited (IN) | 2008-08-06 | — | — | EP | disclosed |
| EP-1144425-B1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LAB LTD (IN) | 2004-06-16 | — | — | EP | disclosed |
| CN-1343212-A | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | disclosed |
| US-6329344-B1 | UREA DERIVATIVE OF ALKYLENE DIOXYFURAN ETHERS | RANBAXY LABORATORIES LIMITED (IN) | 2001-12-11 | — | — | US | disclosed |
| EP-1144425-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042053-A1 | DERIVATIVES OF MONOSACCHARIDES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300196-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, ASGR1, CSGALNACT1 | CALCRL 1491/4885DPP4 393/4885CASP3 1412/4885 |
| US-20090048186-A1 | Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents | HLA-DRB1, MUC1, ASGR1 | CALCRL 1433/4885DPP4 330/4885CASP3 1494/4885 |
| US-20090054519-A1 | DERIVATIVES OF MONOSACCHARIDES AS 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15, ALOX15B | CALCRL 4577/4885DPP4 973/4885CASP3 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.